European law firm Carpmaels & Ransford has promoted Jennifer Antcliff to partner in its dispute resolution team in its London office, bringing the total number of partners in the team to five.
The English Court of Appeal has rejected Neurim’s attempt to block sales of a generic version of its insomnia drug made by Mylan ahead of a patent infringement trial.
The UK Supreme Court today has sided with biopharmaceutical company Kymab, allowing its appeal in a suit involving Regeneron and patents covering transgenic mice.
The European Commission has backed voluntary IP licensing as part of its new vaccines strategy.
Switzerland-based Novartis has failed to convince the UK Intellectual Property Office that a trademark applied-for by Boston Healthcare should not be registered.
Swiss healthcare company Roche has partnered with Chinese biotech Innovent Biologics to develop cell therapies and bispecific antibodies.
The European Commission wants to implement a unitary supplementary protection certificate, its top IP official has said.
Monster Energy has failed to block a UK trademark filed by German pharmaceutical company Merck KGaA.
The advocate general has recommended that the Court of Justice of the European Union uphold an almost €94 million fine imposed on Lundbeck for its pay-for-delay scheme.
In a victory for Mylan, the English High Court has rejected Israel-based pharmaceutical company Neurim’s attempt to delay a generic version of its insomnia medication.